Logo Image
  • News
  • Watch
  • Journals
  • Conferences
  • Events
  • Resources
  • CE
  • About AJMC
  • Subscribe
Opinion|Videos|May 5, 2025

Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

Experts discuss how knowledge of lipoprotein(a) (Lp[a]) levels can empower patients in managing atherosclerotic cardiovascular disease (ASCVD) risk factors, how providers can collaborate with patients on Lp(a) testing and risk management, the potential population-level value of improved ASCVD risk assessment, and how the National Lipid Association’s (NLA) recommendation for one-time Lp(a) testing may benefit health systems.

Episodes in this series

Video content above is prompted by the following:

  • How might knowledge of Lp(a) levels empower patients in their management of ASCVD risk factors?
  • How might providers partner with their patients with respect to Lp(a) testing and ASCVD risk management?
  • What value might improved ASCVD risk assessment and risk factor management offer on a population level, such as to a health care system?
  • The NLA recommends Lp(a) testing only once in a patient’s lifetime. How, if at all, might this frequency benefit health systems?

Related Content